At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 1,000 enrolled
Drug / intervention
Anakinradrug
Likely dose
Anakinra 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
suPAR-guided Anakinra Treatment for Validation of the Risk and Early Management of Severe Respiratory Failure by COVID-19: The SAVE Open-label, Non-randomized Single-arm Trial
In Brief
A Phase 2 clinical trial evaluating Anakinra for COVID-19 and 3 related conditions. Completed, enrolled 1,000 participants across 28 sites.
Detailed Summary
In the SAVE study patients with lower respiratory tract infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at high risk for progression to serious respiratory failure will be detected using the suPAR biomarker. They will begin early treatment with anakinra in the effort to prevent progression in serious respiratory failure.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesGreece
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartApr 2020
First PostedApr 2020
Primary CompletionJan 2022
Study CompletionApr 2022
TodayJul 2026
First PostedApr 22, 2020
Enrollment StartApr 15, 2020
Primary CompletionJan 29, 2022
Study CompletionApr 15, 2022
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 6.2 years ago
Interventions
Anakinradrug
Treatment with 100mg Anakinra subcutaneously (sc) once daily for ten days